Brief: Journey Medical Announces Data from Bioavailability Study of DFD-29 vs Solodyn
20/10/2023 13:35
Oct 20 (Reuters) - Journey Medical Corp DERM.O :
* JOURNEY MEDICAL CORPORATION ANNOUNCES DATA FROM
BIOAVAILABILITY
STUDY OF DFD-29 (MINOCYCLINE HYDROCHLORIDE MODIFIED RELEASE
CAPSULES, 40 MG) VERSUS. SOLODYN® (MINOCYCLINE HYDROCHLORIDE
EXTENDED-RELEASE TABLETS, 105 MG)
* JOURNEY MEDICAL CORP - NEW DRUG APPLICATION SUBMISSION TO
FDA
FOR DFD-29 ANTICIPATED IN Q4 OF 2023
* JOURNEY MEDICAL CORP - STUDY DEMONSTRATED SYSTEMIC
EXPOSURE OF
DFD-29 WAS SIGNIFICANTLY LOWER THAN THAT OF SOLODYN (105 MG)
Source text for Eikon: ID:nGNX36XDNp
Further company coverage: DERM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi